norvir
abbvie deutschland gmbh co. kg - ritonavir - hiv infektioner - antivirale midler til systemisk anvendelse - ritonavir er indiceret i kombination med andre antiretrovirale midler til behandling af hiv-1-inficerede patienter (voksne og børn på to år og ældre).
belkyra 10 mg/ml injektionsvæske, opløsning
abbvie a/s - deoxycholsyre - injektionsvæske, opløsning - 10 mg/ml
botox 100 enheder pulver til injektionsvæske, opløsning
abbvie a/s - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 100 enheder
botox 200 enheder pulver til injektionsvæske, opløsning
abbvie a/s - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 200 enheder
botox 50 enheder pulver til injektionsvæske, opløsning
abbvie a/s - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 50 enheder
litak
lipomed gmbh - cladribine - leukæmi, hårete celler - antineoplastiske midler - litak er indiceret til behandling af hårcellel leukæmi.
xaluprine (previously mercaptopurine nova laboratories)
nova laboratories ireland limited - 6-mercaptopurinmonohydrat - leukæmi, lymfoid - antineoplastiske midler - xaluprine er indiceret til behandling af akut lymfoblastisk leukæmi (all) hos voksne, unge og børn.
purimmun 50 mg tabletter
2care4 generics aps - mercaptopurin - tabletter - 50 mg
fludarabinphosphat "teva" 25 mg/ml koncentrat til injektions-/infusionsvæske, opløsning
teva b.v. - fludarabinphosphat - koncentrat til injektions-/infusionsvæske, opløsning - 25 mg/ml
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.